(PharmaNewsWire.Com, March 06, 2017 ) According to Publisher, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs has experienced robust market growth. Some of the factors which are triggering the market growth include growing incidences of diseases, rising demand for biosimilars drugs owing to their cost effectiveness and increasing demand to limit healthcare expenditures. However, stringent government regulations will affect biosimilars investments.
Some of the key players in this market include are Mylan, Inc., Dr. Reddy's Laboratories, Amgen Inc., Sandoz International GmbH , Hospira, Inc., Merck KGAA, Celltrion, Inc., Biocon Ltd. , Teva Pharmaceutical Industries Ltd. and Roche Diagnostics.
Regions Covered: - North America o US o Canada o Mexico - Europe o Germany o France o Italy o UK o Spain o Rest of Europe - Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific - Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
